References: al-Shamkhani A, Birkeland ML, Puklavec M, Brown MH, James W, Barclay AN. 1996. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol. 26(8):1695-9.
Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S. 2001. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol. 167(11):6669-77.
Bansal-Pakala P, Jember AG, Croft M. 2001. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med. 7(8):907-12.
Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. 2000. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 165(6):3043-50.
Higgins LM, McDonald SAC, et al. 1999. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 162(1):486-93. (IHC frozen, PubMed)
Nakae S, Saijo S, et al. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 100(10):5986-90. (IHC frozen and FA, PubMed)
Andarini S, Kikuchi T, et al. 2004. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 64(9):3281-7. (IHC frozen, PubMed)